A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.

被引：0
|
作者：
Ali, Haris
Kishtagari, Ashwin
Maher, Keri Renee
Mohan, Sanjay
Mazumder, Amitabha
Chamoun, Kamal
Karasik, Igor
Sbar, Eric
Dugon, Laura
Tamir, Sharon
Wang, Xulong
Prchal, Josef T.
Tantravahi, Srinivas Kiran
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Mt Sinai St Lukes Roosevelt Hosp, New York, NY USA
[3] VCU Massey Canc Ctr, Richmond, VA USA
[4] Vanderbilt Univ Sch Med, Nashville, TN USA
[5] Oncol Inst Hope Innovat, Tampa, FL USA
[6] Karyopharm Therapeutics Inc, Newton, MA USA
[7] Karyopharm Therapeut, Newton, MA USA
[8] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[9] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7060
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
    Gutierrez, M. E.
    Giaccone, G.
    Liu, S. V.
    Rajan, A.
    Guha, U.
    Halfdanarson, T. R.
    Curtis, K. K.
    Kunz, P. L.
    Gabrail, N.
    Hinson, J. M.
    Orlemans, E. O.
    ANNALS OF ONCOLOGY, 2016, 27
  • [12] Phase I, Open-label, Dose-Escalation Study of SNX-5422 Plus Everolimus in Neuroendocrine Tumors (NETs)
    Gutierrez, Martin E.
    Giaccone, Giuseppe
    Liu, Stephen V.
    Rajan, Arun
    Guha, Udayan
    Halfdanarson, Thorvardur
    Kunz, Pamela
    Hinson, James M., Jr.
    Orlemans, Everardus O.
    PANCREAS, 2018, 47 (03) : 339 - 339
  • [13] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Hamadani, Mehdi
    Collins, Graham P.
    Caimi, Paolo F.
    Samaniego, Felipe
    Spira, Alexander
    Davies, Andrew
    Radford, John
    Menne, Tobias
    Karnad, Anand
    Zain, Jasmine M.
    Fields, Paul
    Havenith, Karin
    Cruz, Hans G.
    He, Shui
    Boni, Joseph
    Feingold, Jay
    Wuerthner, Jens
    Horwitz, Steven
    LANCET HAEMATOLOGY, 2021, 8 (06): : E433 - E445
  • [14] CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY
    Stemmer, S. M.
    Benjaminov, O.
    Medalia, G.
    Ciuraru, N. B.
    Silverman, M. H.
    Bar-Yehuda, S.
    Fishman, S.
    Harpaz, Z.
    Farbstein, M.
    Cohen, S.
    Patoka, R.
    Singer, B.
    Kerns, W. D.
    Fishman, P.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S555 - S555
  • [15] CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
    Stemmer, Salomon M.
    Benjaminov, Ofer
    Medalia, Gal
    Ciuraru, Noab B.
    Silverman, Michael H.
    Bar-Yehuda, Sara
    Fishman, Sari
    Harpaz, Zivit
    Farbstein, Motti
    Cohen, Shira
    Patoka, Renana
    Singer, Barak
    Kerns, William D.
    Fishman, Pnina
    ONCOLOGIST, 2013, 18 (01): : 25 - 26
  • [16] Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
    Kudo, Toshihiro
    Murai, Yoshiyuki
    Kojima, Yoshitsugu
    Uehara, Kenji
    Satoh, Taroh
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 354 - 362
  • [17] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Moshe Talpaz
    Susan Erickson-Viitanen
    Kevin Hou
    Solomon Hamburg
    Maria R. Baer
    Journal of Hematology & Oncology, 11
  • [18] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
    Talpaz, Moshe
    Erickson-Viitanen, Susan
    Hou, Kevin
    Hamburg, Solomon
    Baer, Maria R.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [19] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [20] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
12345